Ellsworth Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.37M Buy
125,533
+3,836
+3% +$220K 1.21% 29
2026
Q1
$7.38M Buy
121,697
+5,782
+5% +$337K 1.39% 23
2025
Q4
$6.56M Buy
115,915
+9,938
+9% +$478K 1.3% 22
2025
Q3
$4.62M Buy
105,977
+4,485
+4% +$209K 0.99% 40
2025
Q2
$4.7M Buy
+101,492
New +$4.98M 1.14% 40
2023
Q3
Sell
-10,623
Closed -$679K 168
2023
Q2
$679K Buy
10,623
+482
+5% +$32.3K 0.23% 77
2023
Q1
$703K Buy
10,141
+1,467
+17% +$103K 0.25% 70
2022
Q4
$626K Buy
8,674
+1,754
+25% +$132K 0.23% 69
2022
Q3
$492K Buy
6,920
+465
+7% +$33.7K 0.21% 73
2022
Q2
$497K Buy
6,455
+3,316
+106% +$253K 0.2% 72
2022
Q1
$243K Buy
+3,139
New +$211K 0.09% 127
2021
Q3
Sell
-3,357
Closed -$224K 150
2021
Q2
$224K Sell
3,357
-62
-2% -$4.04K 0.11% 138
2021
Q1
$216K Sell
3,419
-199
-6% -$12.4K 0.13% 134
2020
Q4
$224K Buy
3,618
+31
+0.9% +$1.91K 0.16% 108
2020
Q3
$216K Hold
3,587
0.22% 77
2020
Q2
$211K Buy
+3,587
New +$215K 0.23% 70

Other funds holding BMY

Ellsworth Advisors's BMY Position: Q2 2026 in Review

Ellsworth Advisors increased its Bristol-Myers Squibb (BMY) stake by 3.2% in Q2 2026, buying an estimated $220K and bringing the position to 125,533 shares worth $7.37M. The position accounts for 1.21% of the portfolio, ranked #29.

Ellsworth Advisors first reported a position in BMY in Q2 2020 and has held it in 16 quarters since. The position peaked at $7.38M in Q1 2026. 808 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Ellsworth Advisors held 125,533 shares of Bristol-Myers Squibb worth $7.37M as of Q2 2026.
  • Ellsworth Advisors bought 3,836 Bristol-Myers Squibb shares in Q2 2026, an estimated $220K.
  • Bristol-Myers Squibb made up 1.21% of Ellsworth Advisors's portfolio in Q2 2026, its #29 holding.
  • Ellsworth Advisors first reported a position in Bristol-Myers Squibb in Q2 2020 and has held it in 16 quarters since.
  • Ellsworth Advisors's Bristol-Myers Squibb position peaked at $7.38M in Q1 2026.
  • 808 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.